2022
DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation
Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, Xu ML, Cui W, Zhao Y, Halene S, Al-Kali A, Viswanatha D, Chen D, He R, Zheng G. DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Frontiers In Oncology 2022, 12: 849376. PMID: 35296003, PMCID: PMC8918526, DOI: 10.3389/fonc.2022.849376.Peer-Reviewed Original ResearchWorse progression-free survivalProgression-free survivalMyelodysplastic syndromeAML transformationMyeloid neoplasmsMDS casesHigh riskR882 mutationsClonal hematopoiesisIndependent risk factorUnique clinicopathologic featuresTertiary medical institutionsDifferent treatment approachesUnique clinicopathologicExcess blastsSevere leukopeniaClinicopathologic featuresMutant patientsRisk factorsLarge cohortTherapeutic implicationsTreatment approachesClinical implicationsClinical-genomic databaseNeoplasms
2021
Gamma–Delta T‐cell Lymphomas
Foss F, Ahmed A, Xu M. Gamma–Delta T‐cell Lymphomas. 2021, 203-210. DOI: 10.1002/9781119671336.ch15.Peer-Reviewed Original ResearchGamma-delta T-cell lymphomaT-cell lymphomaHepatosplenic T-cell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaFive-year overall survivalCentral nervous system prophylaxisGamma delta T cellsWorld Health Organization classificationAggressive T-cell lymphomaExtensive skin ulcerationsCurative stem cell transplantationChronic antigenic stimulationStem cell transplantationInnate immune systemMost chemotherapeutic agentsSystemic methotrexateSystem prophylaxisMedian survivalMost patientsOverall prognosisOverall survivalClinical featuresOrganization classificationRisk factors